Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Sandrine Aspeslagh

Sandrine Aspeslagh
Country

Belgium

Address
Institute Jules Bordet
Department of Medical Oncology
Brussels

Dr Sandrine Aspeslagh is a medical oncologist and is working at the Department of Medical Oncology at Institute Jules Bordet, Brussels, Belgium. Her main interests are immunotherapy, skin cancers, immune related adverse events and patient communication.

She obtained her PhD in immunology in 2012 at Ghent University through her work with iNKT cells in cancer models in the lab of Prof Dirk Elewaut (rheumatology). The promising results of anti-CTLA-4 immunotherapy made her choose oncology for her further sub-specialisation. Since then she has been working to apply the successes from the immunology research to patients and particularly cancer patients. In 2014, Dr Aspeslagh obtained the Georges Mathé prize for her research in immunotherapy, which gave her the opportunity to join the Drug Development Department (DITEP) at Gustave Roussy Cancer Center in Paris, in the team of Prof Jean-Charles Soria and Dr Aurélien Marabelle. Over the last 2 years, she was the principal investigator of 3 phase I trials and co-investigator for more than 60 Phase I trials (of which at least 20 immunotherapeutical trials). She is organising bi-weekly immune-oncology courses for residents both at DITEP and Institut Jules Bordet, in order to prepare oncologists for the future of immune-oncology.

Dr Aspeslagh is co-author of several publications on immunotherapy and targeted therapy. She is still actively participating to the Immunotoxicity Tumour Board at Gustave Roussy Cancer Centre and is very actively involved in the development of the Immunomanager, an online webtool of the BSMO (Belgian Society of Medical Oncology) on how to deal with immune related adverse events.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings